TL;DR
This study introduces a novel reporter system to precisely track HOXA9 expression in MLL-rearranged leukemia, enabling a high-throughput CRISPR screen. This approach identified USF2 as a key transcription factor regulating HOXA9, offering new therapeutic targets for this aggressive cancer.
What Problem Does This Paper Address?
HOXA9 is a critical gene in aggressive leukemias, but its precise regulation in these diseases remains poorly understood. This knowledge gap hinders the development of effective therapies. Existing methods for studying HOXA9 regulation are limited, particularly in identifying the full network of transcription factors that control its expression. The authors aim to overcome these limitations by creating a sophisticated reporter system and using it to conduct a comprehensive screen for HOXA9 regulators in MLL-rearranged (MLLr) B-ALL, a particularly aggressive form of leukemia.
Methods
The core of this research is the development of a HOXA9-mCherry knock-in reporter cell line. This system uses CRISPR/Cas9 technology to insert a fluorescent mCherry tag directly into the HOXA9 locus, allowing real-time monitoring of endogenous HOXA9 expression. This reporter line then served as the platform for a genome-wide CRISPR/Cas9 loss-of-function screen targeting 1,639 human transcription factors. By analyzing which gene knockouts led to changes in mCherry fluorescence (and thus HOXA9 expression), the researchers could identify key regulatory genes. They also employed Cut&Run assays to pinpoint the direct binding sites of identified transcription factors on the HOXA9 promoter.
Datasets
The study utilized publicly available datasets for context, including:
- GSE13159: for HOXA9 expression profiling in various leukemia lineages and survival analysis.
- European Genome-phenome Archive (EGA): for transcriptome data from a large cohort of B-ALL patients.
- ENCODE dataset: for ChIP-seq data to assess transcription factor occupancy and chromatin status.
No new benchmark datasets were introduced.
Key Insights and Ideas
- A robust reporter system is crucial: The development of the HOXA9-mCherry reporter line was a critical enabler, allowing for precise, real-time monitoring of endogenous HOXA9 expression in a way that standard methods couldn't.
- USF2 emerges as a key regulator: The CRISPR screen unexpectedly identified USF2, a transcription factor not previously strongly linked to HOXA9 regulation in this context, as a significant positive regulator. This highlights the power of unbiased screening.
- CTCF's role is context-dependent: While CTCF is known to be important for chromatin organization and gene regulation, this study found it dispensable for maintaining HOXA9 expression in their specific MLLr B-ALL cell line, suggesting cell-type-specific roles for this factor.
- Synergistic action of USF1 and USF2: The research suggests that USF1 and USF2 may work together to regulate HOXA9, pointing to a complex regulatory network.
Key Results
- The HOXA9-mCherry reporter cell line accurately recapitulated endogenous HOXA9 expression and was responsive to known regulators like DOT1L and ENL.
- A CRISPR screen identified USF2 as a novel, top-ranked positive regulator of HOXA9 in MLLr leukemia.
- Depletion of USF2 significantly reduced HOXA9 expression and impaired leukemia cell proliferation.
- USF2 was shown to directly bind to the HOXA9 promoter.
- USF1 and USF2 were found to synthetically regulate HOXA9 expression, meaning their combined depletion had a greater effect than individual depletion.
- CTCF was found to be dispensable for HOXA9 expression in the studied MLLr SEM cells, contrary to findings in other leukemia subtypes.
Limitations and Future Work
- Cell-type specificity: The authors acknowledge that the role of CTCF in regulating HOXA9 expression might be cell-type-specific, as their findings differed from studies in AML cell lines. Future work could explore this further.
- Mechanism of USF1/USF2 synergy: While the study shows USF1 and USF2 act synergistically, the precise molecular mechanisms of this synergy require further investigation.
- Therapeutic potential: The identification of USF2 as a key regulator opens avenues for developing targeted therapies. Further studies are needed to explore the therapeutic efficacy and safety of targeting this axis.
- Broader HOXA9 regulome: The study focused on transcription factors, but the authors suggest that further investigation into non-coding elements and epigenetic modifiers could provide a more comprehensive understanding of the HOXA9 regulome.
Summary updated